CFN Media Group (“CannabisFN”), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article discussingLexaria Bioscience (OTCQB:LXRP,CSE:LXX) recent product launches and the closing of the company’s private placement.
Lexaria Bioscience (OTCQB:LXRP,CSE:LXX) recently announced the launch of its TurboCBD™ brand of enhanced, high-absorption, full-spectrum hemp oil capsules. The capsules incorporate the company’s patented absorption technology — proven to increase CBD absorption by five to ten times compared to conventional preparations — along with the finest American Ginseng and Ginkgo Biloba to support enhanced focus and memory as well as reduced stress and fatigue.
The market for cannabidiol (“CBD”) is expected to grow to a $2.1 billion market in consumer sales by 2020, according to the Hemp Business Journal, with about $450 million of those sales coming from hemp-based sources. While there are plenty of companies involved in selling hemp-based CBD products, there are few options for solving the problems associated with the bioavailability of CBDs, which tends to be lacking in many products.
In addition to TurboCBD™, the company plans to launch other capsule formulations utilizing its patented absorption technology to address specific market demands. Management is also developing and seeking opportunities to leverage its technology for tetrahydrocannabinol (“THC”) product applications through licensees in the United States, Canada, and other countries around the world — potentially opening the door to new markets.
Lexaria has leveraged a combination of public and private capital to support the development of its innovative portfolio of products. With this combination, the company is able to offset some of its research and development expenses to bring products to market more quickly and effectively than ever possible.
On April 3, the company announced the completion of a brokered private placement of 4,104,280 units at a price of US$0.42 each for total gross proceeds of US$1,723,798. The units of the offering consist of one common share and one-half share purchase warrant at a price of US$0.60 per share for a 24-month period. The proceeds of the offering will be used to advance the research and development of its patented delivery technology.
In addition the company raised in excess of US$1 million in recent months from existing shareholders who have exercised existing warrants and stock options.
The most recent capital raise also marks the first time ever that the company has a runway of greater than one year, which will help limit future dilution. In fact, Lexaria is better capitalized today than at any point in its history, giving the company its best-ever opportunity to leverage its technology to the benefit of its B2B partners.
Looking Ahead
Lexaria Corp. (OTCQB: LXRP) is uniquely positioned to capture market share within the $2.1 billion CBD industry. With its innovative delivery system, the company’s products offer significantly enhanced bioavailability compared to competing products. The recent launch of new products and secured financing opens the door to significant revenue growth ahead and investors may want to keep a close eye on the stock.

About CFN Media


CFN Media (CannabisFN), the leading creative agency and media network dedicated to legal cannabis, helps marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.

Click here to learn more about Lexaria Bioscience (OTCQB:LXRP,CSE:LXX).

Source: www.marketwired.com

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to provide a corporate update on its psychedelic pharmaceuticals program. Since its inception, the Company has built a unique product pipeline for novel uses of ketamine, psilocybin and undisclosed psychedelics. PharmaTher is positioning itself to partner its psilocybin program and panaceAI™, and focus on advancing its novel ketamine product pipeline in Parkinson’s disease, depression and pain via the U.S. Food and Drug Administration (“FDA”) regulatory pathway.

“We have made tremendous progress over the last several months that saw our product pipeline evolve to focus on the massive opportunity and potential of ketamine, an FDA approved drug with a known safety profile, to treat significant unmet medical needs for Parkinson’s disease, depression and pain,” said Fabio Chianelli, CEO of PharmaTher. “With our focus on ketamine through repurposing, combining it with an FDA approved drug and delivering it with our novel microneedle delivery system, we are now positioned to expedite our clinical development objectives by taking advantage of the FDA’s 505(b)(2) regulatory pathway and commercializing disruptive ketamine treatments for mental health and pain disorders.”

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN), Aurora Cannabis (NYSE: ACB)(TSX: ACB), and Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED).

Cannabis leaders are focusing on innovation in premium branding, global expansion, and tight operational execution in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders:

Keep reading... Show less

Chemesis International Inc. (the “Company”) (CSE:CSI)(OTCQB:CADMF)(FRA:CWAA

The Company announces that its (former) subsidiary, Natural Ventures PR, LLC (“NVPR”), has sold all of its cannabis assets, and assigned all related liabilities, licenses and permits, to Puerto Rico Industrial Commercial Holdings Biotech Corp. (“PRICH”) in exchange for immediate net cash proceeds to the Company, in respect of its 80% interest in NVRP, of US$450,000. The Company notes that, in connection with, and as a condition to, this transaction, it will cease to be a shareholder of NVPR.

Keep reading... Show less

Progressive Planet Solutions Inc. (TSXV: PLAN) (“PLAN” or “Progressive Planet”), an emerging leader in reducing the carbon footprint of cement products using natural pozzolans, is pleased to announce it has sold and optioned a combined total of 10 million of its 10.5 million shares of Snow Lake Resources.

The sale and option agreements were made with two arms-length purchasers. The first sale was for 1,700,000 shares at $0.04 per share for a total of $68,000 and includes an option granted by PLAN entitling the same party to purchase an additional 4,966,666 shares at $0.04 per share until May 11, 2021 . The second sale was for 1,250,000 shares at $0.04 per share for a total of $50,000 and includes an option granted by PLAN to such party to purchase an additional 2,083,334 shares until August 14, 2021 . As at the date of this news release, PLAN has received $116,000 and will receive another $284,000 if the remaining shares are purchased under the option agreements.

Keep reading... Show less

First Products to Hit California Shelves in Q2 2021

 4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that its fully funded state of the art 185,000 square foot production facility in Commerce, California is nearing completion and will be ready to serve the $3b California cannabis market in Q2 2021. The project is on target to be completed in April 2021 with the Company planning for the first of its full line of edibles, tinctures and vape products to be on California retail shelves by May.

Keep reading... Show less